Venture funding drops again, but there’s no need to panic yet.
Novo Nordisk hopes that its attempt to preserve beta cells will fare better than Caladrius’s, while Aslan tries its hand at DHODH inhibition.
As the plot thickens around the trigger for Aveo’s equity raise, the EU regulator considers pulling the group's renal cancer drug from the market.
The industry’s most advanced oncolytic virus project, Pexa-Vec, faces a make-or-break pivotal study readout.
A study of a liquid biopsy and another looking at tumour mutational burden testing give early indications of Foundation’s approval strategy.
Encouraging early data from an academic trial of Clovis's Rubraca raise hopes that Parps could emerge as a more tolerable maintenance therapy for some pancreatic…
After two checkpoint combo trials flopped last month Syndax celebrates an unexpected win in a third.
Survival data confirm the value of Astellas’s FLT3-targeting approach in acute myelogenous leukaemia.
With one cancer blood test established on the market Guardant is starting down the road to validating another – this time as a screening assay.